抑制受体相互作用蛋白激酶1改善实验性非酒精性脂肪性肝病
在非酒精性脂肪性肝病(NAFLD)中,肝细胞可发生由受体相互作用蛋白激酶1(RIPK1)介导的程序性坏死。本研究在高脂饮食喂养的小鼠和原代人脂肪变性肝细胞中评估了RIPK1抑制剂RIPA-56的作用,并检测了NAFLD患者血清中RIPK1和MLKL的浓度。结果显示,RIPA-56可下调MLKL,减轻肝损伤、炎症、纤维化和脂肪变性;RIPK1和MLKL可能作为NAFLD活动度的血清标志物和治疗靶点。
要点
- RIPK1抑制剂RIPA-56在预防和治疗高脂饮食小鼠中均减轻NASH特征和脂肪变性。
- RIPA-56或MLKL抑制剂necrosulfonamide可逆转原代人脂肪变性肝细胞的脂肪变性。
- NAFLD患者血清RIPK1和MLKL浓度与疾病活动度相关。
核心结论
- 抑制RIPK1可通过MLKL依赖机制改善高脂饮食小鼠的NASH特征并逆转脂肪变性。
- RIPK1和MLKL是NAFLD潜在的活动度血清标志物和治疗靶点。
研究设计与样本
- C57/BL6J小鼠喂养正常饲料或高脂饮食,评估RIPA-56的预防和治疗效果。
- 在原代人脂肪变性肝细胞和脂肪负载的AML-12小鼠肝细胞中验证机制。
- 检测NAFLD患者血清中RIPK1和MLKL浓度。
主要发现
- RIPA-56预防或治疗高脂饮食小鼠可下调MLKL,减少肝损伤、炎症、纤维化和脂肪变性。
- RIPA-56或necrosulfonamide处理原代人脂肪变性肝细胞可重现脂肪变性减轻。
- Mlkl敲除的脂肪负载AML-12肝细胞线粒体呼吸激活、β氧化增加。
- Ripk3敲除小鼠在实验性NASH中肝线粒体呼吸链复合物活性增加。
- NAFLD患者血清RIPK1和MLKL浓度升高并与活动度相关。
临床怎么用
- RIPK1和MLKL可能作为NAFLD活动度的血清标志物用于监测。
- RIPK1抑制剂代表NAFLD的潜在治疗策略,尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In non-alcoholic fatty liver disease (NAFLD), hepatocytes can undergo necroptosis: a regulated form of necrotic cell death mediated by the receptor-interacting protein kinase (RIPK) 1. Herein, we assessed the potential for RIPK1 and its downstream effector mixed lineage kinase domain-like protein (MLKL) to act as therapeutic targets and markers of activity in NAFLD. METHODS: C57/BL6J-mice were fed a normal chow diet or a high-fat diet (HFD). The effect of RIPA-56, a highly specific inhibitor of RIPK1, was evaluated in HFD-fed mice and in primary human steatotic hepatocytes. RIPK1 and MLKL concentrations were measured in the serum of patients with NAFLD. RESULTS: When used as either a prophylactic or curative treatment for HFD-fed mice, RIPA-56 caused a downregulation of MLKL and a reduction of liver injury, inflammation and fibrosis, characteristic of non-alcoholic steatohepatitis (NASH), as well as of steatosis. This latter effect was reproduced by treating primary human steatotic hepatocytes with RIPA-56 or necrosulfonamide, a specific inhibitor of human MLKL, and by knockout (KO) of Mlkl in fat-loaded AML-12 mouse hepatocytes. Mlkl-KO led to activation of mitochondrial respiration and an increase in β-oxidation in steatotic hepatocytes. Along with decreased MLKL activation, Ripk3-KO mice exhibited increased activities of the liver mitochondrial respiratory chain complexes in experimental NASH. In patients with NAFLD, serum concentrations of RIPK1 and MLKL increased in correlation with activity. CONCLUSION: The inhibition of RIPK1 improves NASH features in HFD-fed mice and reverses steatosis via an MLKL-dependent mechanism that, at least partly, involves an increase in mitochondrial respiration. RIPK1 and MLKL are potential serum markers of activity and promising therapeutic targets in NAFLD. LAY SUMMARY: There are currently no pharmacological treatment options for non-alcoholic fatty liver disease (NAFLD), which is now the most frequent liver disease. Necroptosis is a regulated process of cell death that can occur in hepatocytes during NAFLD. Herein, we show that RIPK1, a gatekeeper of the necroptosis pathway that is activated in NAFLD, can be inhibited by RIPA-56 to reduce not only liver injury, inflammation and fibrosis, but also steatosis in experimental models. These results highlight the potential of RIPK1 as a therapeutic target in NAFLD.
引用
- Majdi A, Aoudjehane L, Ratziu V, et al. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol. 2019. PMID: 31760070. doi:10.1016/j.jhep.2019.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。